Casper N Bang1, Anders M Greve2, Lars Køber2, Anne B Rossebø3, Simon Ray4, Kurt Boman5, Christoph A Nienaber6, Richard B Devereux7, Kristian Wachtell8. 1. Department of Medicine, Weill Cornell Medical College, NY, USA; Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark. Electronic address: casperbang@hotmail.com. 2. Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark. 3. Department of Cardiology, Oslo University Hospital, Norway. 4. Department of Cardiology, Manchester Academic Health Sciences Centre, Manchester, United Kingdom. 5. Institution of Public Health and Clinical Medicine, Umeå University, Medicine Skellefteå, Sweden. 6. Department of Cardiology, Universitätsklinikum Rostock, Germany. 7. Department of Medicine, Weill Cornell Medical College, NY, USA. 8. Department of Medicine, Weill Cornell Medical College, NY, USA; Department of Cardiology, Glostrup University Hospital, Copenhagen Denmark.
Abstract
BACKGROUND:Renin-angiotensin system inhibition (RASI) is frequently avoided in aortic stenosis (AS) patients because of fear of hypotension. We evaluated if RASI with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) increased mortality in patients with mild to moderate AS. METHODS: All patients (n=1873) from the Simvastatin and Ezetimibe in Aortic Stenosis study: asymptomatic patients with AS and preserved left ventricular (LV) ejection fraction were included. Risks of sudden cardiac death (SCD), cardiovascular death and all-cause mortality according to RASI treatment were analyzed by multivariable time-varying Cox models and propensity score matched analyses. RESULTS: 769 (41%) patients received RASI. During a median follow-up of 4.3 ± 0.9 years, 678 patients were categorized as having severe AS, 545 underwent aortic valve replacement, 40 SCDs, 103 cardiovascular and 205 all-cause deaths occurred. RASI was not associated with SCD (HR: 1.19 [95%CI: 0.50-2.83], p=0.694), cardiovascular (HR: 1.05 [95%CI: 0.62-1.77], p=0.854) or all-cause mortality (HR: 0.81 [95%CI: 0.55-1.20], p=0.281). This was confirmed in propensity matched analysis (all p>0.05). In separate analyses, RASI was associated with larger reduction in systolic blood pressure (p=0.001) and less progression of LV mass (p=0.040). CONCLUSIONS:RASI was not associated with SCD, cardiovascular or all-cause mortality in asymptomatic AS patients. However, RASI was associated with a potentially beneficial decrease in blood pressure and reduced LV mass progression.
RCT Entities:
BACKGROUND: Renin-angiotensin system inhibition (RASI) is frequently avoided in aortic stenosis (AS) patients because of fear of hypotension. We evaluated if RASI with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) increased mortality in patients with mild to moderate AS. METHODS: All patients (n=1873) from the Simvastatin and Ezetimibe in Aortic Stenosis study: asymptomatic patients with AS and preserved left ventricular (LV) ejection fraction were included. Risks of sudden cardiac death (SCD), cardiovascular death and all-cause mortality according to RASI treatment were analyzed by multivariable time-varying Cox models and propensity score matched analyses. RESULTS: 769 (41%) patients received RASI. During a median follow-up of 4.3 ± 0.9 years, 678 patients were categorized as having severe AS, 545 underwent aortic valve replacement, 40 SCDs, 103 cardiovascular and 205 all-cause deaths occurred. RASI was not associated with SCD (HR: 1.19 [95%CI: 0.50-2.83], p=0.694), cardiovascular (HR: 1.05 [95%CI: 0.62-1.77], p=0.854) or all-cause mortality (HR: 0.81 [95%CI: 0.55-1.20], p=0.281). This was confirmed in propensity matched analysis (all p>0.05). In separate analyses, RASI was associated with larger reduction in systolic blood pressure (p=0.001) and less progression of LV mass (p=0.040). CONCLUSIONS: RASI was not associated with SCD, cardiovascular or all-cause mortality in asymptomatic AS patients. However, RASI was associated with a potentially beneficial decrease in blood pressure and reduced LV mass progression.
Authors: Shmuel Chen; Bjorn Redfors; Tamim Nazif; Ajay Kirtane; Aaron Crowley; Ori Ben-Yehuda; Samir Kapadia; Matthew T Finn; Sachin Goel; Brian R Lindman; Maria C Alu; Katherine H Chau; Vinod H Thourani; Torsten P Vahl; Pamela S Douglas; Susheel K Kodali; Martin B Leon Journal: Eur Heart J Date: 2020-02-21 Impact factor: 35.855
Authors: Casper N Bang; Anders M Greve; Anne B Rossebø; Simon Ray; Kenneth Egstrup; Kurt Boman; Christoph Nienaber; Peter M Okin; Richard B Devereux; Kristian Wachtell Journal: J Am Heart Assoc Date: 2017-11-27 Impact factor: 5.501
Authors: Ignacio J Amat-Santos; Pablo Catalá; Felipe Diez Del Hoyo; Jose A Fernandez-Diaz; Juan H Alonso-Briales; María Del Trigo; Ander Regueiro; Pablo Juan-Salvadores; Vicenç Serra; Enrique Gutierrez-Ibanes; Antonio J Muñoz-García; Luis Nombela-Franco; Manel Sabate; Victor A Jimenez-Diaz; Bruno García Del Blanco; Javier López; Luis H Varela-Falcón; Teresa Sevilla; Roman Arnold; Ana Revilla; J Alberto San Roman Journal: BMJ Open Date: 2018-02-13 Impact factor: 2.692
Authors: Christian Basile; Ilaria Fucile; Maria Lembo; Maria Virginia Manzi; Federica Ilardi; Anna Franzone; Costantino Mancusi Journal: J Clin Med Date: 2021-11-26 Impact factor: 4.241
Authors: Sachin S Goel; Neal S Kleiman; William A Zoghbi; Michael J Reardon; Samir R Kapadia Journal: J Am Heart Assoc Date: 2020-09-06 Impact factor: 5.501